Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2007

Organon and Dyax Ink Antibody Pact

  • Organon and Dyax will work together to discover and develop human therapeutic antibodies for the treatment of autoimmune diseases and cancer. Dyax will utilize its phage-display technology to find antibodies directed toward a target identified at Organon’s research center in Cambridge, MA.

    “It is our strategy to expand the portfolio of commercially attractive biotech products,” remarks David Nicholson, executive vp R&D of Organon. “Dyax’ state-of-the-art phage-display technology will help us to strengthen our R&D pipeline of antibody therapies for cancer and autoimmune disorders.”

    According to the terms of the collaboration, Dyax will receive license fees and research funding as well as milestone payments and royalties.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »